Tag Archive
Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes (News-Medical-Net)
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth... »
Makefield Therapeutics gets licensed patent covering biodegradable Hybrid Nanoparticles (PharmaBiz)
Makefield Therapeutics, Inc, an emerging therapeutics company, has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles, a versatile new drug delivery platform. (get the story…) Related items Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform (News-Medical-Net) Nanoparticles-safe and effective treatment for... »
Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform (News-Medical-Net)
Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform. (get the story…) Related items Makefield Therapeutics gets licensed patent covering biodegradable Hybrid Nanoparticles (PharmaBiz) Nanoparticles-safe and effective treatment... »
Cancer Therapeutics and Nanotherapies sign letter of intent (News-Medical-Net)
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. (get the... »
Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC (Marketwire via Yahoo! Finance)
SALT LAKE CITY, UT–(Marketwire - 10/16/09) - Cancer Therapeutics, Inc. (OTC.BB: CTHP - News ), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a... »
